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Abstract
Background: In this study we explored the role of microRNAs (miRNAs) as mediators of leukemogenic effects of
the fusion gene MLL-AF9, which results from a frequent chromosomal translocation in infant and monoblastic acute
myeloid leukemia (AML).
Methods: We performed a specific and efficient knockdown of endogenous MLL-AF9 in the human monoblastic
AML cell line THP1.
Results: The knockdown associated miRNA expression profile revealed 21 MLL-AF9 dependently expressed miRNAs.
Gene ontology analyses of target genes suggested an impact of these miRNAs on downstream gene regulation via
targeting of transcriptional modulators as well as involvement in many functions important for leukemia maintenance as
e.g. myeloid differentiation, cell cycle and stem cell maintenance. Furthermore, we identified one of the most intensely
repressed miRNAs, miR-511, to raise CCL2 expression (a chemokine ligand important for immunosurveillance), directly
target cyclin D1, inhibit cell cycle progression, increase cellular migration and promote monoblastic differentiation. With
these effects, miR-511 may have a therapeutic potential as a pro-differentiation agent as well as in leukemia vaccination
approaches.
Conclusions: Our study provides new insights into the understanding of miRNAs as functional mediators of
the leukemogenic fusion gene MLL-AF9 and opens new opportunities to further investigate specific
therapeutic options for AML via the miRNA level.
Keywords: Leukemia, AML, MLL, MLL-AF9, microRNA, miR-511, cyclin D1, CCND1, Differentiation, Monocytic
differentiation
Background
MLL-AF9 (alias KMT2A-MLLT3) is a fusion gene result-
ing from the chromosomal translocation t(9;11)(p22;q23).
It is sufficient to initiate acute leukemia in murine models
[1, 2] and is the most frequent fusion gene in infant acute
myeloid leukemia (AML) and especially associated with
monoblastic AML (FAB-classification M5) [3, 4]. For this
type of leukemia with a persisting poor prognosis, new
targeted therapies are needed.
MLL and AF9 wildtype proteins lead to transcrip-
tional initiation (MLL) and elongation (AF9) of target
genes [5, 6], while the fusion protein MLL-AF9 is believed
to combine these properties, leading to increased activa-
tion of target genes [7]. Novel therapeutic strategies which
aim to directly intervene with MLL-AF9 functions are
under investigation but struggle with the complexity to
target the involved protein-protein and protein-DNA in-
teractions and with the obstacle to avoid targeting of the
important wildtype protein functions [5, 7].
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MicroRNAs (miRNAs) are important cellular posttran-
scriptional gene regulators and are involved in presum-
ably all physiological and pathophysiological cellular
processes [8], including oncological state, progression
and clinical outcome [9–11].
Although technical challenges – predominantly the
specific, efficient and safe delivery of miRNA modulators
to the tumor site – remain to be overcome, miRNA
therapeutics are believed to hold huge promise for can-
cer treatment [12]. In this context, a comprehensive un-
derstanding of the role of miRNAs within the complex
regulatory networks in malignant cells is a prerequisite
for the development of combinatorial therapeutic strat-
egies employing miRNA modulators [12].
As fusion gene breakpoints vary between individual
patients, siRNA-targeting of oncogenic fusion genes
themselves would have to be tested and optimized in
each case and thus does not represent an opportune
therapeutic option. Finding common, relevant down-
stream miRNA targets of MLL-AF9 instead might yield
new alternative therapeutic routes. This approach has
the benefit that oncogenic transcription factors or other
protein classes which are currently non-druggable by
e.g. small molecule drugs might be targeted via miRNA
modulators. Another advantage of miRNA therapeutics
is the fact that not only single gene transcripts can be
targeted (e.g. via target site blockage) but also whole ar-
rays of mRNAs, which may cooperate to create an onco-
genic phenotype (e.g. via miRNA mimics or inhibitors).
In order to identify new alternative drug targets for
MLL-AF9 positive AML, we thus aimed to explore the
role and function of miRNAs as mediators of
leukemogenic effects of the fusion gene MLL-AF9. To
this end, a differential miRNA expression profile was
generated after knockdown of endogenous MLL-AF9 in
the monoblastic AML cell line THP1 and revealed 21
miRNAs predicted to be involved in leukemogenic func-
tions. Additionally, we provide evidence for a relevant
role of miR-511 in the context of monoblastic differenti-
ation. To our knowledge, this is the first experimental
study that comprehensively analyzes the effects of an
MLL fusion gene on miRNA expression.
Methods
Cells, cell cultivation, small interfering RNA and
transfection
Cultivation and siRNA treatment of THP1 cells (DSMZ
GmbH, Braunschweig, Germany) was performed as pre-
viously reported [7]. Briefly, the cell line was authenti-
cated via MLL-AF9 breakpoint sequencing, was
routinely checked for mycoplasma contamination and
transfected with 50 nM Silencer Select siRNAs (Life
Technologies, Carlsbad, CA, USA) and Dreamfect (OZ
Biosciences, Marseille, France) leading to transfection
efficiencies and survival rates of 93 % each. Experimental
incubations lasted eight days with repeated transfections
on day 0, 3, and 6. Prior to each transfection event, cell
densities were determined and cells were reseeded at
5 × 104 cells per ml [7].
THP1 miRNA mimic transfections were performed as
described for siRNA transfections but with 30 nM
Ambion Pre-miR miRNA Precursors (hsa-miR-511-5p
AM10237, neg Control #1 AM17110, neg Control
#2 AM17111) and experimental incubations up to day
nine again with repeated transfections on day 0, 3, and 6.
Human CD14+ monocytes (C-12909, PromoCell GmbH,
Heidelberg, Germany) were cultivated for 48 h in mono-
nuclear cell medium (PromoCell) prior to immunostaining
and RNA isolation. Human CD34+ progenitor cells (C-
12921, PromoCell) were directly taken to RNA isolation.
RNA isolation and reverse transcription quantitative PCR
assays and arrays
Total RNA was extracted with miRNeasy Mini Kit (Qia-
gen, Hilden, Germany) according to the supplier’s proto-
col. For miRNA profiling, RNA of five independent
experiments was pooled for each of the four distinct
siRNA treatments to reduce inter-experimental variation.
According to the supplier’s protocol, quantitative
miRNA profiles of 664 distinct miRNAs were generated
employing 350 ng total RNA per array card, preamplifi-
cation step and TaqMan Array Human MicroRNA Cards
v2.0 (also known as TaqMan Low Density Arrays
(LDAs)) on an ABI PRISM 7900HT machine with SDS
2.3 software (all Life Technologies). LDA raw data were
imported into the statistical language R version 2.11.1
[13]. As it is sometimes difficult to define reliable house-
keeper in the case of miRNAs, it has been shown that
normalizing to the overall mean instead may outperform
the reference approach [14]. Thus, a cyclic LOESS
normalization was applied to the data (separately for the
A and B plates). Analysis of differential expression be-
tween MLL-AF9 knockdown and control treatments was
carried out in the statistical language R with the limma
package [15]. Adjustment for multiple testing was done
using the method by Benjamini and Hochberg [16].
Log2FC, p-value of the moderated t-test and p-value
after correcting for multiple testing were generated.
MiRNAs which showed low expression, i.e. high thresh-
old cycle (CT values above 34.5) in both treatment
groups were excluded from the analysis. MiRNAs with a
p-value below 0.05 were regarded as differentially
expressed. MiRNAs which were either turned “on” or
“off” in both MLL-AF9 knockdown versus both non-
targeting control samples (“undetermined” versus CTs
below 34.5) were added to the miRNA candidate list
manually. For these, no ratio can be calculated but a
lower limit of differential expression is reported as
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previously described [17]. Of the 664 distinct miRNAs
detectable by this LDA, 72 are measured in duplicate.
MiRNAs were removed from the candidate list if their
replicate did not show concordant regulation. MiRNA
profiling data have been deposited in and approved by
NCBI’s Gene Expression Omnibus (GEO) [18] and are
available under the accession number GSE70525.
For LDA validation, pooled RNA samples from two
additional, independent replicate experiments was sub-
jected to quantitative real time PCR via single TaqMan®
miRNA assays after megaplex reverse transcription with
TaqMan MicroRNA Reverse Transcription Kit (Life
Technologies) and preamplification according to the
manufacturers’ instructions. For this purpose, the follow-
ing miRNA assays were used (Life technologies, assay
IDs given in parentheses): hsa-miR-214 (002306), −219-
5p (000522), −369-3p (000557), −432 (001026), −511-5p
(001111), −539 (001286), −576-5p (002350), −582-3p
(002399), −589 (002409), −758 (001990) and −760
(002328). RNU6B (001093), RNU44 (001094) and
RNU48 (001006) assays were tested as internal references.
RNU48 showed the least intra- and inter-experimental
variance and thus was used as internal reference. Spear-
man’s rank correlation coefficient including p-value was
calculated with the statistical language R version 2.11.1
[13]. MiR-511 quantification in further experiments was
performed via TaqMan miRNA assays after concurrent (2-
plex) reverse transcription for hsa-miR-511 and the in-
ternal reference RNU48 from 200 ng total RNA.
For gene expression quantification, reverse transcrip-
tion quantitative PCR (RT-qPCR) was carried out in
triplicates with 600 ng total RNA input, QuantiTect Re-
verse Transcription Kit (Qiagen) and iQ-SYBR Green
Supermix (Biorad, Hercules, CA, USA) on a StepOne-
Plus instrument (Life Technologies) according to the
supplier’s protocol. RPL13A and UBC, showing stable
expression in bone marrow [19], were used as reference
genes. Data were analyzed with StepOne software v 2.1
(Life Technologies) and the ΔΔCT method. Primers were
designed utilizing Clone Manager Suite 7 (Sci-Ed Soft-
ware, Cary, NC, USA) and validated for efficiency via
cDNA dilution series and for specificity via PCR-product
analysis on agarose gels and melt curve analysis. Primer
sequences are provided in Additional file 1: Table S1.
Gene expression profiling analysis
Human Whole Genome Microarrays 4x44K v2 (Agilent
Technologies, Santa Clara, CA, USA) were commissioned
to and performed at IMGM Laboratories (Martinsried,
Germany). For hybridization, 100 ng RNA of two inde-
pendent THP1 experiments (harvested two days after
transfection with miR-511 or negative control #1 mimics)
were utilized. RNA concentration and purity (abs 260/
280 nm) were analyzed using a Nanodrop ND-1000
Spectrophotometer (Nanodrop Technologies, Wilmington,
DE, USA). RNA integrity was determined with an RNA
6000 Nano LabChip Kit on a 2100 Bioanalyzer (Agilent
Technologies). A260/A280 was above 2.0 and RNA integ-
rity number was above 9.5. Between-array normalization
was performed with the quantile method.
Analysis of differential expression was carried out in R
[13] with the limma package [15, 20]. Adjustment for mul-
tiple testing was done using the method by Benjamini and
Hochberg [16].
Probes were considered as differentially expressed at a
p-value of the moderated t-test below 0.05 and signifi-
cant alteration over all identical replicate probes (t-test,
p < 0.05). Gene expression profiling data have been de-
posited in and approved by NCBI’s Gene Expression
Omnibus (GEO) [18] and are available under the acces-
sion number GSE70490.
Functional bioinformatics
MiRTarBase v4.5 [21] was used to extract known, vali-
dated miRNA targets of the set of 21 MLL-AF9 depend-
ently expressed miRNAs. Likewise, TargetScan release
6.2 [22] was employed to predict putative targets of this
set of miRNAs.
Functional annotation analysis (Database for Annota-
tion, Visualization and Integrated Discovery version 6.7,
DAVID) [23, 24] was performed with validated miRNA
targets from miRTarBase (excluding those with weak ex-
perimental evidence) as well as with putative miRNA
targets predicted via TargetScan.
MiRNA targets with strong experimental support in
miRTarBase underlie individual experimental validation
for each miRNA-target gene interaction. As this requires
considerable experimental effort, miRTarBase targets will
not represent a random selection of genes but have a
bias for genes with known, important biological and
pathophysiological functions. It is thus not surprising to
find an enrichment for disease- and cancer-related gene
ontology terms in any subset of genes listed in miRTar-
Base (especially for those with strong experimental sup-
port). Due to this bias, we did not interpret these gene
ontology results in respect to their magnitude of enrich-
ment but rather used the resulting ontology terms as a
description of the biological roles these miRNA target
genes are known to play. To integrate the cellular back-
ground, we regarded only those miRNA targets for these
analyses, which were expressed in our THP1 gene ex-
pression profile [7].
To limit the bias of speculative interference of Tar-
getScan predictions, we employed a stringent context +
score cutoff of at least −0.4 or +0.4 for the sum of all
miRNA-target gene interactions to regard a gene as pre-
dicted target of one or more of our set of miRNAs. The
context + score is given by TargetScan and represents
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the likelihood of a miRNA-target interaction ( MTI). To
compile the sum of context + scores, MTIs of down-
regulated miRNAs (in MLL-AF9 knockdown) retained
negative context + score values (original TargetScan values),
while context + score values of MTIs of up-regulated miR-
NAs were modified to positive values. As recommended,
DAVID gene ontology enrichment was regarded as signifi-
cant if fold enrichment was ≥ 1.5 and p-value < 0.1.
Functional disease ontology (FunDO) [25] was per-
formed with differentially expressed genes in miR-511
mimic treated THP1 cells to extract genes involved in
cancer and leukemia.
Vector construction and luciferase reporter assay
FGFR3 and PDGFA full length 3′UTRs were amplified
from THP1 genomic DNA and THP1 cDNA respect-
ively, CCND1 full length 3′UTR was amplified and sub-
cloned from an pcDNA3.1LacZ-CCND1-3′UTR vector
[26] (generously provided by Katherine L.B. Borden,
Université de Montréal, Canada). Overlapping PCR was
used to introduce CCND1-3′UTR deletions of miR-511
binding site seed regions predicted via the algorithms
DianaMiRExtra, TargetScan, DIANA-microT-CDS (v5.0)
and miRDB. All 3′UTRs were cloned into siCHECK2
vector (Promega, Madison, Wisconsin, USA) and fully
sequenced (Eurofins Genomics, Ebersberg, Germany) to
confirm correct 3′UTR sequences.
Luciferase reporter assays were performed after trans-
fection of HEK-293 cells with vector (100 ng/well) in
combination with either miR-511 or negative control
mimic (20 pmol/well). Experiments were carried out in
24-well format with 7.5 × 104 cells seeded in 1 ml
medium (DMEM high glucose, 10 % FCS) 24 h prior to
transfection with 2 μl Lipofectamine 2000 (Life Technolo-
gies). Cells were harvested 24 h after transfection and
Dual-Luciferase® Reporter Assays (Promega, Fitchburg,
WI, USA) were performed according to supplier’s protocol
on a Fluostar Optima (BMG Labtech GmbH, Ortenberg,
Germany).
Biological assays and flow cytometry analyses
Cell numbers and proliferation rates were determined
via MoxiZ automated cell counter (Orflo, Ketchum, ID
83340, USA).
Cell cycle analyses were performed in combination
with anti-CCND1 staining via flow cytometry. Cells were
fixed in cold methanol at −20 °C, blocked with human
IgG (I 2511, Sigma-Aldrich, St. Louis, MO, USA) and
stained with FITC Mouse Anti-Human Cyclin D1 Anti-
body Set (#554109, BD Biosciences, Franklin Lakes, NJ,
USA,) and propidium-iodide (0.1 % Triton X-100,
0.2 mg/ml RNase A, 20 μg/ml propidium-iodide in PBS)
and analyzed on a BD FACSCanto (BD Biosciences). Cell
doublets and aggregates were removed by gating and the
proportion of cells in G0/G1, S and G2 phase were
quantified with Watson Pragmatic model in FlowJo ver-
sion 9.7.2 (FlowJo LLC, Ashland, Oregon, USA).
Colony forming capacity was analyzed by plating 200
THP1 cells in 200 μl (10000 cells/ml) 0.5 % methyl cellu-
lose (64630, Sigma-Aldrich) / RPMI1640 (10 % FCS) in
24-well plates. Colonies were counted in microscopic
images taken after 10 and 14 days by Cellscreen system
(Innovatis, Bielefeld, Germany) on an Olympus IX 50
microscope (Olympus, Tokyo, Japan).
The effect on monocytic cell differentiation was ana-
lyzed via flow cytometry and surface staining with AF488
mouse anti-human CD11b, PE mouse anti-human CD38
and isotype control antibodies (BD561687, BD557702,
BD560981, BD555749, BD Biosciences) after blocking Fc
receptors with FcR blocking reagent (BD564220, BD Bio-
sciences). To establish CD11b and CD38 flow cytometric
measurements and for determining effects of differenti-
ation on miR-511 expression, THP1 cells were treated
with 0.25 – 5.0 ng/ml PMA (P1585, Sigma-Aldrich) and
monocyte / macrophage differentiation was confirmed via
cell adherence, morphological changes (cell protrusions,
fusiform cells) and growth arrest.
Cellular migration was analyzed in transwell assays
(5 μm pore size, #3421, Corning, NY, USA) with 1 × 105
THP1 cells in RPMI1640 / 10 % FCS in upper chamber
and RPMI1640 with 10 % FCS and 0.1 mM ascorbic acid
in lower chamber. Cells in lower chamber were counted
by MoxiZ cell counter (Orflo) and in microscopic im-
ages taken after 20 h by Cellscreen System (Innovatis).
To test for significant differences between treatments,
student’s t-tests were performed.
Results
MLL-AF9 depletion leads to changes in miRNA expression
To explore if expression of the leukemogenic fusion
gene MLL-AF9 (KMT2A-MLLT3) leads to changes in
miRNA expression, a specific and efficient knockdown
of endogenous MLL-AF9 was performed in the human
monoblastic AML cell line THP1 as previously described
[7]. To exclude siRNA off-target effects, these experi-
ments employed two distinct MLL-AF9 specific as well
as two distinct control siRNAs. Experimental incuba-
tions lasted eight days with repeated transfections on
day 0, 3, and 6. Knockdown reduced MLL-AF9 to 22.3 ±
6 % residual expression on transcript level and to 8 ±
4 % on protein level on day 8 of experiments. MLL and
AF9 wildtype transcript levels were not significantly al-
tered. Additionally, mRNA reduction of HOXA9 (a
known direct target of MLL-AF9) to 56.9 ± 8 % residual
expression confirmed the knockdown on functional pro-
tein level [7].
In this setting, we previously reported a specific gene
expression signature shaped by MLL-AF9 together with
Fleischmann et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:9 Page 4 of 15
affected downstream processes and new potential thera-
peutic targets [7].
The specificity of the knockdown experiments was
confirmed by (1) the presence of important marker genes
and (2) the detection of significant enrichments of direct
MLL-AF9 targets identified in a mouse model and (3) of
genes downstream of MLL-AF9 identified in transduced
primary human cells [7]. Here, we analyzed the correspond-
ing miRNA expression profile (on experimental day 8) with
the goal to detect additional MLL-AF9 dependent effects
via this important posttranscriptional regulatory mechan-
ism. MiRNA profiling data have been deposited in and ap-
proved by NCBI’s Gene Expression Omnibus (GEO) [18]
and are available under the accession number GSE70525.
We detected 21 miRNAs as differentially expressed
upon MLL-AF9 depletion (Fig. 1). For this analysis,
miRNA expression was screened via TaqMan low density
arrays (LDAs) and revealed above background detection
of 53 % of all 664 analyzed miRNAs. Among those, 15
reached significant differential expression (p < 0.05) and
additional 6 miRNAs were either turned “on” or “off” in
both MLL-AF9 knockdown versus both control treat-
ments. For these, no exact ratio can be determined but -
as previously described [17] - a lower limit of differential
expression was determined (Fig. 1). A significant correl-
ation between LDA data and single-assay RT-qPCR data
(performed on pooled samples from two additional inde-
pendent experiments) for 11 of the differentially expressed
miRNAs (p 0.03, Spearman’s Rho 0.66) supported the
screening results (Additional file 2: Figure S1).
Functional role of miRNAs as conferred from validated
and predicted miRNA targets
Experimentally confirmed targets (extracted from miR-
TarBase v4.5 [21]) of MLL-AF9 dependently expressed
miRNAs, which were expressed in THP1 cells, were
used to identify functions and pathways impaired by
MLL-AF9 fusion gene via miRNA expression. MiRTar-
Base held 328 validated miRNA-target interactions
(MTIs) for 14 out of our set of 21 MLL-AF9 depend-
ently expressed miRNAs. However, we excluded 265 of
these, which were marked for weak experimental sup-
port, leaving 63 MTIs with strong experimental support.
To integrate the cellular background, we regarded only
those miRNA targets for these analyses, which were
expressed in our THP1 gene expression profile [7]. This
resulted in 56 remaining MTIs and contained 44 genes as
validated targets for 10 out of our set of 21 differentially
expressed miRNAs. In order to interpret the functional
roles which these miRNAs may exert via these known 44
target genes, we performed a gene ontology analysis with
DAVID software [23, 24] (Additional file 1).
Fig. 1 Differentially expressed miRNAs after MLL-AF9 knockdown in THP1 cells. TaqMan low density array analysis was utilized for quantification of
differential expression which is shown relative to non-targeting control siRNA treatments. Bars indicate standard error of the mean. Columns on
the right show log2 fold change (log2FC) and p-value of the corresponding miRNA. For miRNAs which were turned “on” or “off”, i.e. not detectable in
either both control or both MLL-AF9 knockdown treatments, a lower limit of differential expression is reported as described in methods. Here no p-value
can be calculated. n.c., not calculable
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To structure the results, we manually selected biological
relevant terms in the context of myeloid leukemia, ex-
cluded redundant terms and assorted the terms to higher-
order terms (Additional file 2: Figure S2). The results espe-
cially indicated a role of the targets – and thus inferred a
role of the miRNAs – in proliferation and apoptosis, in
functions related to monocyte/macrophage differentiation
as well as in transcriptional regulation and cancer related
functions. Further analysis revealed that five of the miRNAs
(miR-137, −214-3p, −301a-3p, −330-3p and −383-5p) are
known to target genes affecting all of these four categories
(Additional file 2: Figure S3), implying their relevance for
leukemia as well as the possibility to therapeutically target
gene regulation via these miRNAs.
Confirmed targets with strong experimental support
(as listed in miRTarBase) were known only for a subset
of the MLL-AF9 regulated miRNAs (10 out of 21). As
these miRNA-target studies are not all-encompassing,
these known targets will additionally represent only a
fraction of the actual effective and relevant miRNA tar-
gets. Thus, the performed analysis of known, experimen-
tally confirmed and THP1-expressed direct targets can
only give partial insights into the roles of these miRNAs.
To overcome these limitations, we additionally analyzed
the roles of predicted targets for all of the 21 differen-
tially regulated miRNAs.
Among numerous miRNA target prediction algo-
rithms, TargetScan [22] is the most popular and widely
used and has recently been evaluated to yield one of the
best predictive performances [27]. TargetScan predicted
targets for 19 out of our set of 21 MLL-AF9 dependently
expressed miRNAs. To limit the bias of speculative
interference, we employed a stringent context + score
cutoff to regard a gene as predicted target of one or
more of the set of 19 miRNAs (see methods for details).
Again, only those targets which were expressed in THP1
cells [7] were included in the analyses. This approach
yielded 5500 predicted MTIs concerning 1827 predicted
target genes (most genes were predicted targets of more
than one miRNA) for which gene ontology analyses were
performed via DAVID software (Additional file 3). The
results, filtered for biologically relevant and non-
redundant terms are presented in Fig. 2.
Remarkably, ontology terms concerning cell cycle pro-
gression (G1/S transition of mitotic cell cycle, re-entry
into mitotic cell cycle, positive regulation of cell cycle)
were predominantly predicted as targets of miRNAs up-
regulated in the context of MLL-AF9 depletion, while
terms related to cell cycle checkpoints (cell cycle: G1/S
checkpoint, G2/M transition checkpoint, DNA damage
checkpoint) were predominantly targeted by down-
regulated miRNAs (see sum of context + score of terms
in Fig. 2), implying a cell cycle promoting and check-
point decreasing role of MLL-AF9 via miRNAs.
Stem cell maintenance/development and cellular re-
sponse to stress were predominantly predicted to be tar-
geted by MLL-AF9 dependently down-regulated and up-
regulated miRNAs respectively, suggesting a stem cell
supporting and cellular stress response suppressive role
of MLL-AF9 via miRNAs.
To compare the gene ontology results of MLL-AF9 de-
pendently regulated genes [7] with those of known and
predicted targets of MLL-AF9 dependently regulated
miRNAs, we compiled a table with related gene ontology
terms that were present in at least two of the three data
sets (Table 1). This overview illustrates that genes dir-
ectly involved in the cell cycle, Wnt signaling, adhesion,
myeloid differentiation as well as in the cellular response
to stress are preferentially present in the miRNA target
gene data sets and thus these processes may be preferen-
tially influenced by MLL-AF9 via miRNA expression.
Gene regulatory effects of miR-511 expression in THP1
monoblasts
While the preceding ontology analyses may suggest cer-
tain functional roles of the set of MLL-AF9 differentially
regulated miRNAs in the context of leukemia, one has
to take into account that these functions are always con-
text dependent and will have to be experimentally vali-
dated. To this end, we decided to further experimentally
investigate the functional role of miR-511, one of the
most potently activated miRNAs after MLL-AF9 deple-
tion. Concerning known targets, so far only TRIB2,
TLR4 and CD80 have been validated for miR-511 in
other cellular contexts [28, 29].
To identify targets and effects of miR-511 in monoblasts,
we performed miR-511 up-regulation in THP1 cells by
transfecting miRNA mimics. The subsequently analyzed
gene expression profiles via whole genome arrays revealed
653 probes representing 627 genes to be differentially
expressed between miR-511 and negative control mimic
treatments (profiling data have been deposited in NCBI’s
Gene Expression Omnibus (GEO) [18] and are available
under the accession number GSE70490). Of these, 45 %
were down-regulated. The previously described miR-511
target genes were either not expressed above background
(TRIB2 and CD80) or not differentially regulated (TLR4)
on transcript level in this setting.
Based on links to leukemia or cancer via functional dis-
ease ontology (FunDO [25], Additional file 4) or literature
research, we selected 15 out of 627 differentially expressed
genes after miR-511 up-regulation in THP1 cells for con-
firmation via RT-qPCR (Additional file 2: Table S1). Of
these, five genes were confirmed to be significantly differ-
entially regulated after miR-511 transfection in three add-
itional independent replicate experiments (Fig. 3). These
were the up-regulated genes chemokine (C-C motif) lig-
and 2 (CCL2), matrix metallopeptidase 9 (MMP9) and
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interleukin 1 beta (IL1B) as well as the down-regulated
genes cyclin D1 (CCND1) and platelet-derived growth fac-
tor alpha polypeptide (PDGFA). For fibroblast growth fac-
tor receptor 3 (FGFR3) a trend towards down-regulation
was observed (Fig. 3).
MiR-511 directly regulates cyclin D1
For the three genes which were down-regulated on tran-
scriptional level after miR-511 treatment (CCND1, FGFR3
and PDGFA), luciferase reporter assays were performed to
test for direct miR-511 targeting. Full-length 3′UTRs of
Fig. 2 MiRNA-target gene prediction associated functional annotation terms identified via DAVID. Gene ontology analysis was performed for all
THP1-expressed, targets predicted via TargetScan with a minimum context + score of ±0.4 of MLL-AF9 knockdown associated miRNAs. Annotation
terms were manually assorted to five higher-order terms according to the major role of the process in the biological setting under investigation.
Annotation terms assigned to two higher-order terms are placed between these two and separated by dotted division lines. Some annotations were
abbreviated as indicated by superscript numbers: 1regulation of Wnt receptor signaling pathway, 2positive regulation of Wnt receptor signaling pathway,
3positive regulation of myeloid cell differentiation, 4regulation of transcription from RNA polymerase II promoter, 5stem cell maintenance / stem cell
development (two synonymous terms), 6response to endoplasmic reticulum stress. Columns represent the sum of context + scores for all MTIs of this
term, where MTIs of down-regulated miRNAs (in MLL-AF9 knockdown) retained negative context + score values, context + score values of
MTIs of up-regulated miRNAs received positive values. Thus negative values of this column indicate strong predicted targeting by down-regulated miRNAs
and positive values indicate strong predicted targeting by upregulated miRNAs, while targets which were similarly likely targeted by
up- and down-regulated miRNAs do not reach the sum of context + score cutoff and are not included in the predicted target gene list
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these transcripts were cloned into siCHECK2 vector.
FGFR3- and PDGFA-3′UTRs were not affected by miR-
511 in dual luciferase assays while CCND1-3′UTR was
targeted by miR-511 as indicated by significantly reduced
Renilla luciferase signals (Fig. 4).
To further validate the direct interaction and to deter-
mine which binding sites for miR-511 are relevant for
CCND1 regulation, seed sequences of predicted binding
sites were deleted (Fig. 5a, b) and again dual luciferase
assays were performed. Here, binding site 1 did contrib-
ute significantly to CCND1-downregulation although
only to a small extent, while binding site 2 deletion was
able to completely abrogate regulation through miR-511
(Fig. 5c). Parallel deletion of both binding sites even led
to an up-regulation of protein expression (Fig. 5c).
This phenomenon could be theoretically due to an off-
target binding of the employed negative control mimic
to the Renilla luciferase- or the subsequent 3′UTR-se-
quence. However, using negative control mimic #2 and
no mimic as further controls did yield similar results as
with negative control mimic #1 and thus disagree with
this hypothesis. Another possible explanation would be
an off-target binding of miR-511 to the housekeeping fire-
fly luciferase sequence, however, sequence comparisons
do not support this possibility and, more importantly, the
luciferase expression from the vector without 3′UTR is
not affected by miR-511 treatment (compared to negative
control mimics or no mimic). We thus currently cannot
define the cause of the up-regulatory effect of miR-511 in
luciferase assays when both binding sites were deleted
from CCND1-3′UTR. However, the employed controls in-
dicated that this observation was not due to a miRNA-
mimic off-target binding and that the effect is dependent
on the presence of CCND1-3′UTR.
Table 1 Comparison between gene ontology results of MLL-







DNA replication × Ø ×
apoptosis × × Ø
cell cycle Ø × ×
JAK-STAT signaling × Ø ×
Wnt signaling Ø × ×
cytokine × × Ø
endocytosis × Ø ×
adhesion Ø × ×
lysosome × Ø ×
myeloid differentiation Øa × ×
hemopoiesis × × Ø
transcription factor × × ×
reg of pol II transcription × × ×




Compared were the gene ontology results obtained via DAVID software
between MLL-AF9 dependently expressed genes [7] and known (miRTarBase)
as well as predicted (TargetScan) target genes of MLL-AF9 dependently
expressed miRNAs. × present in the data set, Ø not present in the data set
arefers to gene ontology terms directly concerning myeloid differentiation (e.g.
“regulation of myeloid cell differentiation”), whereas terms indirectly related to
myeloid differentiation (e.g. “phagocytosis”) were also present within the gene
expression profile. Terms in bold letters were preferentially present in the
miRNA target gene data sets
Fig. 3 MiR-511 dependently expressed gene transcripts. Subsequent to introduction of miR-511 mimics in THP1 cells, differential expression of a
subset of potentially important transcripts identified in the gene expression screen was verified in three additional independent experiments via
RT-qPCR on experimental days 3, 6 and 9. Columns indicate log2 fold change (log2FC) between miR-511 and negative control #1 mimic treatments.
Bars indicate standard error. * p < 0.05, ** p < 0.005, *** p < 0.0005
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MiR-511 reduces cyclin D1 protein level and percentage
of cells in S-phase in THP1
In the next step we examined the effect of miR-511 on the
protein expression of cyclin D1 (CCND1) via flow cyto-
metric analysis of cyclin D1 stained THP1 cells transfected
either with miR-511 or control #1 mimic. Time course ex-
periments showed a trend towards reduced cyclin D1 pro-
tein expression on day 6 and significant reduction on day
9 after miR-511 mimic treatment (Fig. 6a).
Due to the experimental design with reseeding of cells
prior to mimic transfections, cell proliferation could only
be assessed over a period of 3 days in a row, within
which no significant difference between miR-511 mimic
and control mimic treatments was observed. Concerning
an effect of miR-511 on the colony formation capacity of
THP1 monoblasts, we observed a significant reduction
of colony numbers after miR-511 mimic treatment when
compared to negative control #2 mimic (p 0.02 for day
10 and 14), but only a trend towards reduced colony
numbers when compared to negative control #1 mimic
(p 0.15 and 0.11 for day 10 and 14 respectively, Fig. 6b).
Cyclin D1 is required for cell cycle G1/S transition
[30]. To test for the corresponding functional effect of
miR-511, we determined the cell cycle distribution of
THP1 cells in miRNA mimic experiments via flow cy-
tometry. Indeed, the percentage of cells in S-phase was
significantly reduced in miR-511 mimic treatments on
experimental days 6 and 9 (Fig. 6c).
MiR-511 is associated with differentiation in THP1 cells
Cyclin D1 has been described to inhibit ligand-induced
PPAR-gamma function [31] while ligand activation of
the PPAR-gamma/retinoid X receptor-alpha heterodimer
in myelomonocytic cell lines is known to induce mono-
cytic differentiation [32, 33]. Thus, expression of the
miR-511 target cyclin D1 may indirectly influence
monocytic differentiation. Additionally, miR-511 has
been described to be upregulated after differentiating
human blood monocytes into macrophages [29]. Con-
cordantly, we observed miR-511 to be significantly up-
regulated (10.8-fold) 24 h after inducing differentiation
Fig. 4 Effect of miR-511 mimic on 3′UTRs of selected genes in a dual
luciferase reporter assay. Columns represent mean over five independent
experiment, bars indicate standard error of the mean. * p< 0.05 in all
replicate experiments
Fig. 5 Effect of miR-511 on CCND1-3′UTR with and without deletion of miR-511 binding site seed regions. a Structural map of siCHECK2 vector:
Wildtype full length CCND1-3′UTR consists of 3192 nucleotides and was cloned into the multiple cloning region located downstream of the Renilla
luciferase translational stop codon of siCHECK-2 vector. Predicted miR-511 binding sites are indicated. b Sequence of miR-511 binding sites as predicted
by the indicated algorithms. CCND1-3′UTR nucleotides complementary to miR-511 are indicated in bold. Positions 2738–2745 of CCND1-001 Ensemble
transcript variant were deleted for binding site 1 seed region (del-1) and positions 4251–4270 for binding site 2 seed region (del-2). c Effect of miR-511
mimic on CCND1-3′UTR with and without seed region deletions in dual luciferase reporter assay. Columns represent mean over three independent
experiments, bars indicate standard deviation; * p≤ 0.05; ** p≤ 0.005; w/o, without
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of THP1 cells via 5 ng/ml phorbol 12-myristate 13-acetate
(PMA) in three independent experiments (p < 0.05). In
this setting, cellular differentiation was confirmed via cell
adherence, morphological changes (cell protrusions, fusi-
form cells) and growth arrest. Additionally, although
representing more differentiated cell types, we observed
the leukemic cell lines THP1 and K562 to express similar
low levels of miR-511 as primary CD34+ hematopoietic
stem/progenitor cells, while primary CD14+ monocytes
expressed significant higher miR-511 levels (Fig. 7).
In this context, we asked if miR-511 is able to promote
cellular differentiation in the AML cell line THP1. For
this purpose, we treated THP1 cells with miR-511 mimic
or negative control mimics and analysed the expression
Fig. 6 Cellular effects of miR-511 mimic treatment in THP1 cells. a Effect of miR-511 mimic treatment on cyclin D1 protein expression of THP1 cells
measured by flow cytometry (median fluorescence intensity). b Mean colony number formed by THP1 cells 10 and 14 days after having
been transfected three times over a time frame of 10 days with miRNA mimics. c Effect of miR-511 mimic treatment on proportion of THP1 cells in S-
phase. d Effect of miR-511 mimic on surface expression of monocytic marker CD38. e Effect of miR-511 mimic treatment on migratory capability of THP1.
On day 8 after miRNA mimic transfection, cells were left migrating through 5 μm transwells for 20 h. Number of migrated cells was counted via MoxiZ cell
counter and Cellscreen microscopy with equal results. f Representative pictures of Cellscreen microscopy of migrated THP1 cells are shown. Columns
show mean over four (a, c) or three (b, d, e) independent experiments, bars indicate standard error of the mean. Black: miR-511 mimic treatment, light
grey: negative control #1 mimic treatment (ctrl-1 mimic), dark grey: negative control #2 mimic treatment (ctrl-2 mimic). * p< 0.05; ** p< 0.005
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of surface myeloid differentiation marker CD11b and
CD38 [34] via flow cytometry. While CD11b was not
expressed above background (isotype control) in any
treatment (Additional file 2: Figure S4), CD38 signal to
noise ratio was significantly higher in miR-511 treated
compared to both negative control mimic treated THP1
cells and this effect intensified over the experimental
time course (Fig. 6d). Compared to CD14+ mono-
blasts, untreated THP1 cells expressed 4.8-fold higher
levels of CD38.
MiR-511 may thus exert pro-differentiation roles in
THP1 cells, as in addition to being a marker for myeloid
differentiation, CD38 has been described to promote cel-
lular differentiation of HL-60 cells in response to 1,25-
dihydroxyvitamin D3 and retinoic acid [34]. As CD38 is
not a predicted target of miR-511 via TargetScan, this ef-
fect of miR-511 on monocytic differentiation is likely
mediated via other target genes.
MiR-511 augments migratory capability of THP1 cells
Migratory capability of myeloid cells is closely linked to
their differentiation status: during normal monocyte
maturation, cells gain the capability of locomotion [35].
In contrast to mature monocytes, AML monoblasts ap-
pear to lack the apparatus necessary for locomotion as
neither chemotaxis nor random migration could be de-
tected in this primary cell type [35].
We thus asked, if miR-511 expression is able to raise
the migratory capability – as a sign of differentiation –
of THP1 monoblasts. Indeed, we were able to observe
that miR-511 mimic treatment significantly augments
the capability of THP1 cells to migrate through 5 μm
transwells (Fig. 6e).
Discussion
We employed a quantitative profiling technique (LDAs)
to analyze differential expression of miRNAs after effi-
cient and specific MLL-AF9 depletion in THP1 cells and
validated the results by single assay RT-qPCR for a subset
of deregulated miRNAs. We excluded off-target effects by
employing two distinct MLL-AF9-targeting as well as two
distinct non-targeting control siRNA treatments and de-
tected 21 miRNAs to be differentially expressed in MLL-
AF9 knockdown versus control treatments.
A causal explanation is still lacking for the majority of
aberrantly expressed miRNAs in acute leukemia and ab-
errant expression of neighboring genes, genomic aberra-
tions and specific regulatory factors can only explain the
minority of dysregulated miRNAs [36]. Our study how-
ever, focused on the role of the epigenetic regulator
MLL-AF9 alone, so that the observed differential regula-
tion of miRNAs may be attributed to this factor.
MiR-196b has been previously described to be upregu-
lated by MLL-AF9 employing Mll knockout or exogen-
ous Mll / Mll-Af9 transduced murine cells [37–39]. We,
however, observed a divergent expression of miR-196b
levels between the two non-targeting control siRNA
treatments which led to the exclusion of this miRNA
from our differential miRNA expression signature.
This observation suggests that siRNAs may have dir-
ect or indirect off-target effects not only on mRNA
expression but also on miRNAs and corroborates the
importance of using adequate controls for off-target
effects in siRNA studies. The high stringency of our
experimental design might thus explain the relatively
low number of differentially expressed miRNAs we
detected. Because miRNA processing is a specifically
regulated process [12], it is not surprising that we did
Fig. 7 Mir-511 expression levels in primary hematopoietic stem / progenitor cells, leukemic cell lines and primary monocytes. MiR-511 expression
level is shown in relation to the cellular differentiation level. *** p < 0.0005
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not detect miRNA host-genes to be differentially
expressed in our data set.
Recently, in a number of in vivo studies, miRNAs have
been found to be differentially expressed among distinct
cytogenetic groups of AML. However, the specific signa-
tures differed among studies, most likely due to the lack
of standardized methods used by different groups [40].
This also includes the use of different miRNA profiling
platforms and versions resulting in diverse coverages of
quantified miRNAs. Nevertheless, some concordance
was detected between our in vitro data set and previ-
ously published in vivo data. MiR-219 was described to
be upregulated in AML with MLL-AF6 and MLL-AF9
versus other AML cases [41], while miR-589 was ob-
served to be upregulated in MLL-rearranged AML ver-
sus normal controls [42].
To interpret possible functional and biological effects
of the MLL-AF9 dependently expressed miRNAs, we
employed in silico gene ontology analyses from 1)
known direct as well as 2) predicted mRNA targets of
these miRNAs. While the first analysis approach has the
advantage to be based on bona fide MTIs instead of
more or less reliable predictions, it is limited by the fact
that only a small portion of actual MTIs have been ex-
perimentally validated up to date and thus this analysis
can only yield a partial view on the actual roles the in-
volved miRNAs play. The analysis approach employing
predicted MTIs on the other hand is able to represent all
miRNAs and a much larger proportion of target interac-
tions, but will be hindered by false positive as well as false
negative MTIs. To obtain the best possible comprehensive
and reliable view on the functional roles these miRNAs
play, we employed both analysis approaches.
We detected the known direct targets of our set of
MLL-AF9 dependently expressed miRNAs to be mainly
involved in proliferation and apoptosis, in functions re-
lated to monocyte / macrophage differentiation as well as
in transcriptional regulation and cancer. Five of the miR-
NAs (miR-137, −214-3p, −301a-3p, −330-3p and −383-5p)
emerged to possess target genes affecting all of these four
categories, which may imply their relevance for leukemia.
The gene ontology analysis of in silico predicted direct tar-
gets of MLL-AF9 dependently expressed miRNA implied
cell cycle promoting and checkpoint decreasing roles as
well as stem cell supporting and cellular stress response
suppressive roles for these miRNAs.
To predict which biological functions may be predom-
inantly influenced by MLL-AF9 via miRNA expression
(as opposed to direct gene regulatory effects of MLL-
AF9), we compared the gene ontology results from our
previously published MLL-AF9 dependent gene expres-
sion profile [7] with the gene ontology results from known
and predicted target genes of MLL-AF9 dependently
expressed miRNAs. This analysis indicated that the cell
cycle, Wnt signaling, adhesion, myeloid differentiation as
well as the cellular response to stress may be preferentially
influenced by MLL-AF9 via miRNA expression.
We observed enriched influence of MLL-AF9 on down-
stream transcriptional regulators both, via gene expression
targeting as well as via miRNA expression targeting of
MLL-AF9. However, due to the relative difficulty to thera-
peutically target transcription factors, e.g. via small mol-
ecule drugs, manipulation of these miRNAs may present a
promising future opportunity to therapeutically tar-
get deregulated gene expression in MLL-AF9 positive
leukemia.
Altogether, these gene ontology analyses show that the
MLL-AF9 dependently expressed miRNAs are presum-
ably involved in many leukemia relevant functions. Is
has to be stressed however, that these analyses are not
able to take into account the extent of MLL-AF9
dependent miRNA expression strength. Additionally,
targeting of single gene transcripts by a miRNA is
dependent on the cellular context and e.g. the present
amount of transcripts from other direct target genes of
that miRNA. Thus, while these analyses may suggest
certain functional roles of the set of MLL-AF9 differen-
tially regulated miRNAs in the context of leukemia,
these functions will have to be experimentally validated.
To venture into this direction, we subsequently ana-
lyzed targets and functional roles of miR-511, which was
one of the most deregulated miRNAs by MLL-AF9. To
this end, we employed miRNA mimic mediated up-
regulation of miR-511 in THP1 cells and subsequently
analyzed a comprehensive gene expression profile as well
as effects on functional level.
We were able to validate significant and strong up-
regulatory effects of miR-511 on the expression of CCL2,
MMP9 and IL1B and significant down-regulatory effects
on PDGFA and cyclin D1. Possible anti-leukemic roles of
miR-511 via anti-angiogenesis, anti-proliferative as well as
pro-differentiation and pro-immunosurveillance effects is
suggested by known roles of these downstream genes in
chemotactic activity [43], AML immunosurveillance [43],
hematopoietic progenitor cell mobilization [44], macro-
phage migration [45], monocytic differentiation [46, 47]
and tumor cell proliferation, angiogenesis and metastasis
[48]. As such, miR-511 might be e.g. an alternative way to
raise immunosurveillance against AML monoblasts via its
effect to induce CCL2 expression.
In addition to its classical role as cell cycle promoter,
cyclin D1 has been reported to be involved in cancer drug
resistance by being suppressed by a miRNA (let-7b), to be
essential for migration in macrophages [49, 50] and might
be indirectly involved in monocytic differentiation via
inhibition of PPAR-gamma function [31], as the PPAR-
gamma/retinoid X receptor-alpha heterodimer in myelo-
monocytic cell lines is known to induce monocytic
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differentiation [32]. Concordantly, we found miR-511 ex-
pression to be significantly higher in monocytes as com-
pared to leukemic cell lines and hematopoietic stem/
progenitor cells.
As miRNAs primarily act via post-transcriptional gene
repression, the observed up-regulatory effects of miR-
511 on CCL2, MMP9 and IL1B may be indirect. Al-
though this does not necessarily lessen their importance
in miR-511 mediated cellular functions, we aimed at val-
idating direct miR-511 targets. To this end we pre-
formed dual luciferase assays with cloned full-length 3′-
UTR sequences of CCND1, FRFG3 and PDGFA and
confirmed a significant repressive effect of miR-511
mimic on cyclin D1 3′UTR. We further succeeded to
experimentally confirm miR-511 binding sites within the
CCND1 3′UTR which validated cyclin D1 as a direct
and specific target of miR-511. While cyclin D1 is not a
direct target of MLL or MLL fusion genes such as MLL-
AF9 [51], this observation is in concordance with the
likelihood of miR-511 targeting as predicted via TargetS-
can, which yielded a context + score of −0.43 for cyclin
D1, while indicating a lower probability for FGFR3 and
PDGFA of being a miR-511 target (context + score −0.11
and not predicted, respectively).
Although the luciferase assays demonstrated cyclin D1
to be a direct target of miR-511, this experimental ap-
proach presents a relatively artificial system with overex-
pression of the target gene 3′UTR cloned into a
luciferase vector and introduced into HEK cells. To ad-
dress the regulation within the relevant cellular context,
we additionally confirmed a suppressive effect of miR-
511 on cyclin D1 protein expression in THP1 mono-
blasts via flow cytometry.
We further aimed to define cellular and functional
consequences of miR-511 expression in the context of
AML monoblasts. To this end, we were able to provide
evidence for miR-511 to reduce the proportion of cells
in S-phase of the cell cycle and to increase the migratory
capability of the cells. Even though we detected THP1
cells to express 4.8-fold higher levels of CD38 compared
to human primary CD14+ monocytes, CD38 is an early
myeloid differentiation marker in myeloblasts [52] and,
importantly, a known differentiation promoting ectoen-
zyme receptor [34]. Thus, miR-511 expression may pro-
mote monoblast differentiation as indicated by the
raised expression of CD38.
As we did not observe significant effects on cellular
proliferation within the experimental time frame (up to
three days), these observations primarily suggest a role
of miR-511 in monoblast differentiation, as cell cycle,
cyclin D1 as well as migratory capability are also linked
to myeloid differentiation: cell cycle lengthening is im-
portant for macrophage differentiation (e.g. via leading
to an accumulation of the hematopoietic transcription
factor PU.1) [53], decrease of cyclin D1 may induce
monocytic differentiation via raised PPAR-gamma/retin-
oid X receptor-alpha function [31, 32] and migratory
capability / locomotion is a trait gained during mono-
blastic differentiation [35]. Thus, besides a potential
therapeutic use in leukemia vaccination approaches via
its strong up-regulatory effect on CCL2 expression
which is known to raise immunosurveillance [43], miR-
511 may prove useful in differentiation treatment strat-
egies. The latter therapeutic approaches stimulate the
leukemic cells to differentiate while often simultaneously
inducing growth arrest and apoptosis [33]. Due to their
usually low toxicity profile, these differentiation treat-
ments may be especially useful in combination regimens
with cytotoxic chemotherapies [33].
Conclusions
We here present a MLL-AF9 dependent miRNA expres-
sion profile encompassing 21 miRNAs and interpret the
signature’s consequences via gene ontology analyses to
influence a wide array of cellular functions important for
leukemia maintenance. A comparison to functional roles
of MLL-AF9 dependent gene expression suggested that
the cell cycle, Wnt signaling, the cellular response to
stress, adhesion as well as myeloid differentiation may
be preferentially influenced by MLL-AF9 via miRNA ex-
pression. Furthermore, many transcriptional regulators
are among the known and predicted miRNA target
genes and thus therapeutic miRNA manipulation may
present a possibility to target these hard-to-drug pro-
teins in the future. We further present miR-511, which
is strongly repressed by MLL-AF9, to upregulate CCL2, a
chemokine ligand important for immunosurveillance, to
directly target the key cell cycle regulator cyclin D1, to
inhibit cell cycle progression, to increase cellular migra-
tion and to promote monoblastic differentiation. With
these effects, miR-511 may have a potential therapeutic
use as a pro-differentiation agent as well as in leukemia
vaccination approaches.
Additional files
Additional file 1: All (non-filtered) gene ontology results of known
miRNAs targets. DAVID gene ontology analysis was performed for all
THP1-expressed, validated direct targets (extracted from miRTarBase) of
MLL-AF9 knockdown associated miRNAs. This file includes all extracted
MTIs extracted from miRTarBase as well as all gene ontology results from
DAVID analysis (clustered and non-clustered terms). (XLSX 125 kb)
Additional file 2: Figure S1: Correlation between miRNA data from
LDA and single assay RT-qPCR after MLL-AF9 knockdown in THP1 cells.
Figure S2: MiRNA-target gene associated functional annotation terms
identified via DAVID (MiRTarBase targets). Figure S3: Venn diagram of
miRNAs involved in relevant biological functions. Figure S4: Effect of
miR-511 mimic on surface expression of monocytic marker CD11b. Table
S1: RT-qPCR Primer information (DOC 673 kb)
Fleischmann et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:9 Page 13 of 15
Additional file 3: All (non-filtered) gene ontology results of predicted
miRNAs targets. DAVID gene ontology analysis was performed for all THP1-
expressed targets predicted via TargetScan with a minimum context + score
of 0.4 of MLL-AF9 knockdown associated miRNAs. This file includes all
predicted MTIs as well as all gene ontology results from DAVID ana-
lysis (clustered and non-clustered terms) with a p-value below 0.1
and a fold enrichment above 1.5. (XLSX 475 kb)
Additional file 4: Functional disease ontology (FunDO) analysis
results of genes differentially regulated by miR-511 mimic treatment.
Analysis was used to extract leukemia and cancer related genes.
(XLSX 22 kb)
Competing interests
The authors have no competing interests.
Authors’ contributions
KKF conceived and designed the study, acquired, analyzed and interpreted
the data and wrote the manuscript. PP performed statistical analyses of array
data and critically revised the manuscript. JvF analyzed and interpreted data
and critically revised the manuscript. TM, AAR and IR participated in the
study conception and design and critically revised the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported in part by the “Mehr LEBEN für krebskranke Kinder
– Bettina Braeu” Foundation, the “Christina-Bergmann” Foundation and the
German Research Foundation GRK 1202: “Oligonucleotides in Cell Biology
and Therapy”. The authors would like to thank Katherine L.B. Borden from
Université de Montréal, Canada, for generously providing pcDNA3.1LacZ-
CCND1-3′UTR vector and Kristin Haehnel and Carola Laudano for excellent
technical assistance.
Author details
1Division of Pediatric Hematology and Oncology, Children’s Research Center,
Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-Universität München,
Lindwurmstrasse 2a, 80337 Munich, Germany. 2Lehrstuhl für
Genomorientierte Bioinformatik, Technische Universität München,
Maximus-von-Imhof-Forum 3, 85354 Freising, Germany. 3Children’s Research
Center, Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-Universität
München, Lindwurmstrasse 2a, 80337 Munich, Germany.
Received: 19 September 2015 Accepted: 3 January 2016
References
1. Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J, et al. The mll-
AF9 gene fusion in mice controls myeloproliferation and specifies acute
myeloid leukaemogenesis. EMBO J. 1999;18(13):3564–74.
2. Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, et al. Malignant
transformation initiated by Mll-AF9: gene dosage and critical target cells.
Cancer Cell. 2008;13(5):432–40.
3. Chowdhury T, Brady HJM. Insights from clinical studies into the role of the MLL
gene in infant and childhood leukemia. Blood Cells Mol Dis. 2008;40(2):192–9.
4. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA,
Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/
MLL-rearranged acute myeloid leukemia: results of an international
retrospective study. Blood. 2009;114(12):2489–96.
5. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica.
2009;94(7):984–93.
6. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular
mechanism for MLL-based leukaemogenesis. Nat Rev Cancer. 2010;10(10):721–8.
7. Fleischmann KK, Pagel P, Schmid I, Roscher AA. RNAi-mediated silencing of
MLL-AF9 reveals leukemia-associated downstream targets and processes.
Mol Cancer. 2014;13(1):27. doi:10.1186/1476-4598-13-27.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell.
2009;136(2):215–33. doi:10.1016/j.cell.2009.01.002.
9. Butrym A, Rybka J, Baczynska D, Tukiendorf A, Kuliczkowski K, Mazur G. Low
expression of microRNA-204 (miR-204) is associated with poor clinical
outcome of acute myeloid leukemia (AML) patients. J Exp Clin Cancer Res:
CR. 2015;34:68. doi:10.1186/s13046-015-0184-z.
10. Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX, Zhong L. Decrease expression
of microRNA-20a promotes cancer cell proliferation and predicts poor
survival of hepatocellular carcinoma. J Exp Clin Cancer Res: CR.
2013;32(1):21. doi:10.1186/1756-9966-32-21.
11. Zhou Y, Huang Z, Wu S, Zang X, Liu M, Shi J. miR-33a is up-regulated in
chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to
cisplatin by down-regulating TWIST. J Exp Clin Cancer Res: CR. 2014;33:12.
doi:10.1186/1756-9966-33-12.
12. Naidu S, Magee P, Garofalo M. MiRNA-based therapeutic intervention of
cancer. J Hematol Oncol. 2015;8(1):68. doi:10.1186/s13045-015-0162-0.
13. R_Development_Core_Team. R. A language and environment for statistical
computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
14. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F,
Speleman F, et al. A novel and universal method for microRNA RT-
qPCR data normalization. Genome Biol. 2009;10(6):R64.
15. Smyth GK. Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol
Biol. 2004;3:Article3.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Royal Stat SocietySeries B
(Methodological). 1995;57(1):289–300.
17. Dorsam ST, Ferrell CM, Dorsam GP, Derynck MK, Vijapurkar U, Khodabakhsh
D, et al. The transcriptome of the leukemogenic homeoprotein HOXA9 in
human hematopoietic cells. Blood. 2004;103(5):1676–84.
18. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, et al. NCBI
GEO: archive for functional genomics data sets - 10 years on. Nucleic Acids
Res. 2011;39 suppl 1:D1005–10.
19. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al.
Accurate normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biology. 2002;3(7):
research0034.1-research.12.
20. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey
V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and Computational
Biology Solutions using R and Bioconductor. New York: Springer;
2005. p. 397–420.
21. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, et al. miRTarBase
update 2014: an information resource for experimentally validated miRNA-
target interactions. Nucleic Acids Res. 2014;42(Database issue):D78–85.
doi:10.1093/nar/gkt1266.
22. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-
pairing stability and high target-site abundance decrease the proficiency of
lsy-6 and other microRNAs. Nat Struct Mol Biol. 2011;18(10):1139–46.
doi:10.1038/nsmb.2115.
23. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources. Nat Protoc.
2009;4(1):44–57.
24. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Res. 2009;37(1):1–13.
25. Osborne JD, Flatow J, Holko M, Lin SM, Kibbe WA, Zhu LJ, et al. Annotating the
human genome with Disease Ontology. BMC Genomics. 2009;10 Suppl 1:S6.
26. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL.
eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in
the 3′UTR. J Cell Biol. 2005;169(2):245–56. doi:10.1083/jcb.200501019.
27. Fan X, Kurgan L. Comprehensive overview and assessment of computational
prediction of microRNA targets in animals. Brief Bioinform. 2014.
doi:10.1093/bib/bbu044.
28. Zhang C, Chi YL, Wang PY, Wang YQ, Zhang YX, Deng J, et al. miR-511 and
miR-1297 inhibit human lung adenocarcinoma cell proliferation by
targeting oncogene TRIB2. PLoS One. 2012;7(10):e46090.
doi:10.1371/journal.pone.0046090.
29. Tserel L, Runnel T, Kisand K, Pihlap M, Bakhoff L, Kolde R, et al. MicroRNA
expression profiles of human blood monocyte-derived dendritic cells and
macrophages reveal miR-511 as putative positive regulator of toll-like
receptor 4. J Biol Chem. 2011;286(30):26487–95.
30. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear
protein required for cell cycle progression in G1. Genes Dev.
1993;7(5):812–21.
31. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, et al.
Cyclin D1 repression of peroxisome proliferator-activated receptor gamma
expression and transactivation. Mol Cell Biol. 2003;23(17):6159–73.
Fleischmann et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:9 Page 14 of 15
32. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma
promotes monocyte/macrophage differentiation and uptake of oxidized
LDL. Cell. 1998;93(2):241–52.
33. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia:
3 decades of development. Blood. 2009;113(16):3655–65.
34. Kauss MA, Reiterer G, Bunaciu RP, Yen A. Human myeloblastic leukemia cells
(HL-60) express a membrane receptor for estrogen that signals and modulates
retinoic acid-induced cell differentiation. Exp Cell Res. 2008;314(16):2999–3006.
35. Glasser L. Functional differentiation in acute monoblastic leukemia. Am J
Clin Pathol. 1981;75(1):122–5.
36. Schotte D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: from
biological players to clinical contributors. Leukemia. 2012;26(1):1–12.
37. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, et al.
Regulation of mir-196b by MLL and its overexpression by MLL fusions
contributes to immortalization. Blood. 2009;113(14):3314–22.
38. Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, et al.
Structure of the MLL CXXC domain-DNA complex and its functional role in
MLL-AF9 leukemia. Nat Struct Mol Biol. 2010;17(1):62–8.
39. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-
rearranged leukemia is dependent on aberrant H3K79 methylation by
DOT1L. Cancer Cell. 2011;20(1):66–78.
40. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The
prognostic and functional role of microRNAs in acute myeloid leukemia.
Blood. 2011;117(4):1121–9.
41. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F,
et al. MicroRNA signatures associated with cytogenetics and prognosis in
acute myeloid leukemia. Blood. 2008;111(6):3183–9.
42. Jiang X, Huang H, Li Z, He C, Li Y, Chen P, et al. miR-495 is a tumor-
suppressor microRNA down-regulated in MLL-rearranged leukemia.
Proc Natl Acad Sci U S A. 2012;109(47):19397–402.
43. Legdeur MC, Broekhoven MG, Schuurhuis GJ, Beelen RH, Ossenkoppele GJ.
Monocyte-chemoattractant-protein-1-mediated migration of human
monocytes towards blasts from patients with acute myeloid leukemia.
Cancer Immunol Immunother. 2001;50(1):16–22.
44. Pruijt JF, Fibbe WE, Laterveer L, Pieters RA, Lindley IJ, Paemen L, et al.
Prevention of interleukin-8-induced mobilization of hematopoietic
progenitor cells in rhesus monkeys by inhibitory antibodies against the
metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci U S A. 1999;
96(19):10863–8.
45. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage
migration requires MMP-9 activation by plasminogen in mice. J Clin
Invest. 2008;118(9):3012–24. doi:10.1172/JCI32750.
46. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O.
Primary human acute myelogenous leukemia cells release matrix
metalloproteases and their inhibitors: release profile and pharmacological
modulation. Eur J Haematol. 2010;84(3):239–51.
47. Chan S, Fung M, Mak N, Leung K. Involvement of interleukin-1 in the
differentiation-inducing activity of tumor necrosis factor-alpha on a murine
myeloid leukemia (WEHI-3B JCS). Int J Oncol. 1997;10(4):821–6.
48. Tripurani SK, Cook RW, Eldin KW, Pangas SA. BMP-specific SMADs function as
novel repressors of PDGFA and modulate its expression in ovarian granulosa
cells and tumors. Oncogene. 2013;32(33):3877–85. doi:10.1038/onc.2012.392.
49. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and
abnormal functions. Endocrinology. 2004;145(12):5439–47.
doi:10.1210/en.2004-0959.
50. Guo Y, Yan K, Fang J, Qu Q, Zhou M, Chen F. Let-7b expression determines
response to chemotherapy through the regulation of cyclin D1 in glioblastoma.
J Exp Clin Cancer Res: CR. 2013;32:41. doi:10.1186/1756-9966-32-41.
51. Wang QF, Wu G, Mi S, He F, Wu J, Dong J, et al. MLL fusion proteins preferentially
regulate a subset of wild-type MLL target genes in the leukemic genome. Blood.
2011;117(25):6895–905. doi:10.1182/blood-2010-12-324699.
52. Lamkin TJ, Chin V, Varvayanis S, Smith JL, Sramkoski RM, Jacobberger JW, et al.
Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells
regulates cell differentiation or viability depending on expression levels. J Cell
Biochem. 2006;97(6):1328–38. doi:10.1002/jcb.20745.
53. Kueh HY, Champhekar A, Nutt SL, Elowitz MB, Rothenberg EV. Positive
feedback between PU.1 and the cell cycle controls myeloid differentiation.
Science. 2013;341(6146):670–3. doi:10.1126/science.1240831.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fleischmann et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:9 Page 15 of 15
